Evaluation of portal pressure by doppler ultrasound in patients with cirrhosis before and after simvastatin administration - a randomized controlled trial

Nadia Elwan, Raafat Salah, Manal Hamisa, Ebtsam Shady, Nehad Hawash, Sherief Abd-Elsalam, Nadia Elwan, Raafat Salah, Manal Hamisa, Ebtsam Shady, Nehad Hawash, Sherief Abd-Elsalam

Abstract

Background: Portal hypertension is one of the most frequent complications of cirrhosis. β-adrenergic blockers, with or without organic nitrates, are currently used as hypotensive agents. Statins such as simvastatin seem to be safe for patients with chronic liver diseases and exert multiple pleiotropic actions. This study aimed to assess PTH using Doppler ultrasound in patients with cirrhosis before and after simvastatin administration. Methods: This randomized controlled clinical trial was conducted on 40 patients with cirrhosis who were randomized into 2 groups: group I included 20 patients with cirrhosis who were administered 20 mg of simvastatin daily for 2 weeks and then 40 mg daily for another 2 weeks, and group II included 20 patients with cirrhosis who did not receive simvastatin as a control group. All patients underwent full clinical examination, laboratory investigations, and abdominal Doppler ultrasound at baseline and after 30 days to evaluate portal vein diameter, blood flow volume, direction and velocity of portal vein blood flow, hepatic artery resistance and pulsatility indices, splenic artery resistance index, portal hypertension index (PHI), liver vascular index, and modified liver vascular index (MLVI). Results: There was a highly significant decrease in the hepatic artery resistance index in group I, from 0.785 ± 0.088 to 0.717 ± 0.086 (P < 0.001). There was a significant decrease in the PHI in group I , from 3.915 ± 0.973 m/sec to 3.605 ± 1.168 m/sec (P = 0.024). Additionally, there was a significant increase in the MLVI in group I from 11.540 ± 3.266 cm/sec to 13.305 ± 3.222 cm/sec, an increase of 15.3% from baseline (P = 0.009). No significant adverse effects were detected. Conclusions: Simvastatin is safe and effective in lowering portal hypertension. [ClinicalTrials.gov Identifier: NCT02994485].

Keywords: Simvastatin; Portal hypertension; Cirrhosis; Doppler; Ultrasound..

Conflict of interest statement

No competing interests were disclosed.

Figures

Figure 1.. Portal hypertension index (PHI) in…
Figure 1.. Portal hypertension index (PHI) in the studied groups.

References

    1. Bosch J, Abraldes JG, Berzigotti A, et al. : The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol. 2009;6(10):573–582. 10.1038/nrgastro.2009.149
    1. Sanyal AJ, Bosch J, Blei A, et al. : Portal hypertension and its complications. Gastroenterology. 2008;134(6):1715–1728. 10.1053/j.gastro.2008.03.007
    1. Bosch J, Abraldes, JG, Groszmann R: Current management of portal hypertension. J Hepatol. 2003;38(Suppl 1):S54–S68. 10.1016/S0168-8278(02)00430-0
    1. Vargas V, Rimola A, Casanovas T, et al. : Applicability of liver transplantation in Catalonia at the end of the millennium (A prospective study of adult patient selection for liver transplantation). Transpl Int. 2003;16(4):270–275.
    1. Failli P, DeFranco RM, Caligiuri A, et al. : Nitrovasodilators inhibit platelet-derived growth factor-induced proliferation and migration of activated human hepatic stellate cells. Gastroenterology. 2000;119(2):479–492. 10.1053/gast.2000.9354
    1. Yu Q, Shao R, Qian HS, et al. : Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension. J Clin Invest. 2000;105(6):741–748. 10.1172/JCI7997
    1. Van de CM, Omasta A, Janssens S, et al. : In vivo gene transfer of endothelial nitric oxide synthase decreases portal pressure in anaesthetised carbon tetrachloride cirrhotic rats. Gut. 2002;51(3):440–445. 10.1136/gut.51.3.440
    1. Morales-Ruiz M, Cejudo-Martn P, Fernández-Varo G, et al. : Transduction of the liver with activated Akt normalizes portal pressure in cirrhotic rats. Gastroenterology. 2003;125(2):522–531. 10.1016/S0016-5085(03)00909-0
    1. de Franchis R: Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2005;43(1):167–176. 10.1016/j.jhep.2005.05.009
    1. Blum A, Shamburek R: The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis. 2009;203(2):325–330. 10.1016/j.atherosclerosis.2008.08.022
    1. Trebicka J, Hennenberg M, Laleman W, et al. : Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology. 2007;46(1):242–253. 10.1002/hep.21673
    1. Violi F, Calvieri C, Ferro D, et al. : Statins as antithrombotic drugs. Circulation. 2013;127(2):251–257. 10.1161/CIRCULATIONAHA.112.145334
    1. Zafra C, Abraldes JG, Turnes J, et al. : Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology. 2004;126(3):749–755. 10.1053/j.gastro.2003.12.007
    1. Berzigotti A, Piscaglia F, EFSUMB Education and Professional Standards Committee : Ultrasound in portal hypertension--part 2--and EFSUMB recommendations for the performance and reporting of ultrasound examinations in portal hypertension. Ultraschall Med. 2012;33(1):8–32; quiz 30-1. 10.1055/s-0031-1299145
    1. Scheinfeld MH, Bilali A, Koenigsberg M: Understanding the spectral Doppler waveform of the hepatic veins in health and disease. Radiographics. 2009;29(7):2081–2098. 10.1148/rg.297095715
    1. McNaughton DA, Abu-Yousef MM: Doppler US of the liver made simple. Radio Graphics. 2011;31(1):161–188. 10.1148/rg.311105093
    1. Bolognesi M, Sacerdoti D, Merkel C, et al. : Splenic Doppler impedance indices: Influence of different portal hemodynamic conditions. Hepatology. 1996;23(5):1035–1040. 10.1002/hep.510230515
    1. Sacerdoti D, Gaiani S, Buonamico P, et al. : Interobserver and interequipment variability of hepatic, splenic, and renal arterial Doppler resistance indices in normal subjects and patients with cirrhosis. J Hepatol. 1997;27(6):986–992. 10.1016/S0168-8278(97)80141-9
    1. Piscaglia F, Donati G, Serra C, et al. : Value of splanchnic Doppler ultrasound in the diagnosis of portal hypertension. Ultrasound Med Biol. 2001a;27(7):893–899. 10.1016/S0301-5629(01)00390-8
    1. Haktanir A, Cihan BS, Celenk C, et al. : Value of Doppler sonography in assessing the progression of chronic viral hepatitis and in the diagnosis and grading of cirrhosis. J Ultrasound Med. 2005;24(3):311–321. 10.7863/jum.2005.24.3.311
    1. Zhang L, Duan YY, Li JM, et al. : Hemodynamic features of Doppler ultrasonography in patients with portal hypertension: intraoperative direct measurement of portal pressure in the portal venous system. J Ultrasound Med. 2007;26(12):1689–1696. 10.7863/jum.2007.26.12.1689
    1. Schuppan D, Afdhal NH: Liver cirrhosis. Lancet. 2008;371(9615):838–851. 10.1016/S0140-6736(08)60383-9
    1. Shateria K, Mohammadib A, Moloudic F, et al. : Correlation between sonographic portal vein diameter and flow velocity with the clinical scoring systems MELD and CTP in cirrhotic patients: is there a relationship? Gastroenterology Research. 2012;5(3):112–119. 10.4021/gr369w
    1. Ong TZ, Tan HJ: Ultrasonography is not reliable in diagnosing liver cirrhosis in clinical practice. Singapore Med J. 2003;44(6):293–295.
    1. Lafortune M, Marleau D, Breton G, et al. : Portal venous system measurements in portal hypertension. Radiology. 1984;151(1):27–30. 10.1148/radiology.151.1.6701328
    1. Al-Nakshabandi NA: The role of ultrasonography in portal hypertension. Saudi J Gastroenterol. 2006;12(3):111–117. 10.4103/1319-3767.29750
    1. Berzigotti A, Seijo S, Reverter E, et al. : Assessing portal hypertension in liver diseases. Expert Rev Gastroenterol Hepatol. 2013;7(2):141–155. 10.1586/egh.12.83
    1. Achim CA, Bordei P, Dumitru E: The role of ultrasonography in the evaluation of portal hemodynamics in healthy adults and pathologic conditions. ARS Medica Tomitana. 2016;22(2):128–134. 10.1515/arsm-2016-0022
    1. Harkanyi Z: Doppler Ultrasound signs of portal hypertension in cirrhosis. Ultrasound Clin. 2006;1(3):443–455.
    1. Gülberg V, Haag K, Rössle M, et al. : Hepatic arterial buffer response in patients with advanced cirrhosis. Hepatology. 2002;35(3):630–634. 10.1053/jhep.2002.31722
    1. Yu Ya F, Ya EV: Possibilities of Doppler ultrasonography in valuing of morfofunctional condition of liver for patients with viral hepatitis and hepatocirrhosis. Intercollegas. 2014;1(1):65–72.
    1. Zhang L, Duan YY, Li JM, et al. : Hemodynamic features of Doppler ultrasonography in patients with portal hypertension: intraoperative direct measurement of portal pressure in the portal venous system. J Ultrasound Med. 2007;26(12):1689–1696. 10.7863/jum.2007.26.12.1689
    1. Elwan N, Salah R, Hamisa M, et al. : Dataset 1 in: Evaluation of portal pressure by doppler ultrasound in patients with cirrhosis before and after simvastatin administration – a randomized controlled trial. F1000Research. 2018.
    1. Bishnu S, Ahammed SM, Sarkar A, Hembram J, Chatterjee S, Das K, Dhali GK, Chowdhury A, Das K: Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study. Eur J Gastroenterol Hepatol.2018;30(1) : 10.1097/MEG.0000000000001006 54-59 10.1097/MEG.0000000000001006
    1. Pollo-Flores P, Soldan M, Santos UC, Kunz DG, Mattos DE, da Silva AC, Marchiori RC, Rezende GF: Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: A randomized controlled trial. Dig Liver Dis.2015;47(11) : 10.1016/j.dld.2015.07.156 957-63 10.1016/j.dld.2015.07.156
    1. Abraldes JG, Villanueva C, Aracil C, Turnes J, Hernandez-Guerra M, Genesca J, Rodriguez M, Castellote J, García-Pagán JC, Torres F, Calleja JL, Albillos A, Bosch J., BLEPS Study Group: Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. Gastroenterology.150(5) : 10.1053/j.gastro.2016.01.004 1160-1170.e3 10.1053/j.gastro.2016.01.004
    1. Abraldes JG, Albillos A, Bañares R, Turnes J, González R, García-Pagán JC, Bosch J: Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology.2009;136(5) : 10.1053/j.gastro.2009.01.043 1651-8 10.1053/j.gastro.2009.01.043

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner